source
- Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher diseaseSanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…
- Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patentNovartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…